Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM).

Keith Flaherty, Adil Daud, Jeffrey S. Weber, Jeffrey Alan Sosman, Kevin Kim, Rene Gonzalez, Omid Hamid, Jeffrey R. Infante, Jonathan S. Cebon, Lynn Mara Schuchter, Georgina V. Long, Alain Patrick Algazi, Ragini Reiney Kudchadkar, Igor Puzanov, Donald P. Lawrence, Amy S. Kline, Elizabeth Ann Cunningham, Peng Sun, Kiran Patel, Richard Kefford

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)9010
Number of pages1
JournalJournal of Clinical Oncology
Issue number15 supplement
Publication statusPublished - 20 May 2014
Externally publishedYes
Event50th Annual Meeting of the American-Society-of-Clinical-Oncology - Chicago, United States
Duration: 30 May 20143 Jun 2014

Cite this